The Central Drugs Standard Control Organization (CDSCO) is advancing a smarter, risk-based regulatory framework aimed at simplifying compliance for Indian pharmaceutical manufacturers while strengthening drug safety oversight. The initiative was…
The Indian government has confirmed that Rs 5,210 crore (approximately $625 million) has been invested under the Production Linked Incentive (PLI) scheme for Key Starting Materials (KSM), drug intermediates, and…
India's drug regulator is signalling a major shift in how it oversees the pharmaceutical industry — moving from a uniform, checklist-based inspection model toward a smarter, risk-based approach that could…
The Indian pharmaceutical sector delivered a strong trio of developments in September 2026 — the iPHEX 2026 expo generated an estimated US$4.5–5 billion in potential business discussions, the domestic market…